BEACHWOOD, Ohio — August 5, 2025 — Leads & Copy — Trailhead Biosystems, Inc. (TrailBio.com) has commercially released TrailBio® Hematopoietic Progenitor Cells. These progenitor cells are derived from a single, well-characterized iPSC line using Trailhead’s proprietary High-Dimensional Design-of-Experiments (HD-DoE®) platform, providing researchers with a consistent, scalable tool for hematopoietic research.
The cells express key hematopoietic markers including CD34, CD43 and CD90 and are designed for applications such as hematopoietic disease modeling, drug screening and hematotoxicity studies. Functional characterization confirms their ability to form myeloid and erythroid colonies in colony-forming unit (CFU) assays, differentiate into multiple hematopoietic lineages and demonstrate hematopoietic commitment through transcriptomic profiling.
According to David Llewellyn, Chief Executive Officer of Trailhead Biosystems, TrailBio® Hematopoietic Progenitor Cells strengthen their portfolio by providing researchers with high-quality, human-relevant cellular models that enable scientists to advance research in hematopoietic biology and therapeutic development.
Angelica Gomes Ueltschy, Scientific Director at Trailhead Biosystems, adds that these Hematopoietic Progenitor Cells deliver a dependable combination of purity, potency and versatility and are well suited for modeling blood disorders and evaluating therapeutic candidates.
For more information, please contact: Tim Mauk, Corporate Communications, Email: info@trailbio.com
Source: TrailBio Biosystems, Inc.
